Propel(X)
VC Fund
San Francisco, United States
Propel(x) is an angel investing platform focused on funding early-stage companies that are built around scientific discovery. The company is driven by a mission to help propel mankind by enabling investments in technologies that matter. Propel(x) was founded in 2014 and is headquartered in San Francisco, California.
- Total investments:
- 108
- Last investment:
- Lead investor:
- 2%
Last updated:
For AI agents: llms.txt
Industries Propel(X) invests in
Stages Propel(X) invests in
Countries Propel(X) invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Seed
- $702k–$4M
- Series A
- $1.8M–$20M
- Series B
- $2M–$41M
Investment Focus
Industry
- Health Care 33 (31%)
- Biotechnology 29 (27%)
- Software 17 (16%)
- Manufacturing 13 (12%)
- Medical Device 12 (11%)
Stage
- Seed 42 (39%)
- Series A 13 (12%)
- Series B 10 (9%)
- Venture - Series Unknown 10 (9%)
- Funding Round 5 (5%)
Country
- United States 87 (81%)
- Canada 2 (2%)
- United Kingdom 2 (2%)
- Singapore 1 (1%)
- Switzerland 1 (1%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Andy Reed
Director
|
Director | Total investments: 0 | Find email | |
Anand V.
Evaluation Contributor - Science and Technology Startups
|
Evaluation Contributor - Science and Technology Startups | Total investments: 0 | Find email | |
Jason Holt
Venture Partner
|
Venture Partner | Total investments: 2 | Find email | |
Jason May
Chief Technology Officer
|
Chief Technology Officer | Total investments: 0 | Find email | |
Joe Panettieri
Member
|
Member | Total investments: 0 | Find email | |
| See all 9 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Cordance Medical
|
Cordance Medical is a medical device company that develops radical therapy for a variety of CNS pathology, including primary and metastatic cancer, Alzheimer's, and Parkinson's diseases. | $8M / Seed / Nov 24, 2025 | |
HEVO
|
HEVO provides a seamless, safe, and, universal wireless charging solution for electric vehicles with its proprietary operating system and wireless power transfer technology. Equivalent to plug-in charging efficiencies, and offering a better user experience, the HEVO system is interoperable between vehicles and well-suited for commercial fleets,shared autonomous vehicles, city infrastructure, destination charging, and ultimately in-road dynamic charging. HEVO's customers include leading global brands in the energy, automotive, and charging industries. HEVO's patented system consists of advanced power electronics, operating software, network management, system communications, and market-leading safety mechanisms. HEVO is a key part of the broader multi-trillion dollar shared, electric, and autonomous mobility revolution. | Venture - Series Unknown / Sep 30, 2025 | |
Xsensio
|
Xsensio develops the unique Lab-on-Skin™ sensing platform to sense in real-time biochemical information at the surface of the skin, providing unprecedented real-time information about our health and wellness, in a simple and non-invasive way.The Xsensio Lab-on-Skin™ sensing chip relies on a unique, highly-miniaturized sensing platform developedat the Nanolab of the Swiss Federal Institute of Technology. By leveraging semiconductor properties, our sensing platform unleashes a whole new set of possibilities in continuous health monitoring. | Series A / Jun 20, 2025 | |
Probius
|
Probius specializes in providing services from biomarker discovery to quantification. | Venture - Series Unknown / May 30, 2025 | |
AGEMICA
|
Agemica is a biotechnology company dedicated to developing vaccines and therapies aimed at aging and age-related diseases. The company offers preventative treatments that address multiple chronic conditions simultaneously, such as cancer, rather than treating each disease in isolation. Using artificial intelligence and large-scale biological data,Agemica integrates information from numerous cancers, one million drug and biologic signatures, and extensive microbial and nutrition datasets. | Venture - Series Unknown / May 07, 2025 | |
Trailhead Biosystems
|
Trailhead Biosystems is a developer of cell therapy using hardware and software services. The company merges developmental biology and cell therapeutics with hardware and computerized experimental design and analysis to perform process-specific parameter optimization for customers seeking to develop cell therapies. Implementing Quality by Design(QbD) principles, cell culture optimization is done by utilizing the Design of Experiment (DoE) theory combined with Multivariate Data Analysis (MVDA). This allows the company to generate mathematical models of the biological system, understand the effector-response relationship in cell culture, and provide a systems biology analysis of the differentiation space. | $20M / Venture - Series Unknown / May 06, 2025 | |
Cage Bio
|
Cage Bio is a privately-held clinical-stage company exploiting its proprietary deep eutectic ionic liquid platform to develop novel products for dermatology, inflammation, and immunology. The company's mission is to develop highly effective topical products for localized treatment thereby minimizing side effects from systemic exposure.CageBio is headquartered in San Carlos, California. | Venture - Series Unknown / Apr 30, 2025 | |
Akston Biosciences
|
Akston Biosciences Corporation leverages its novel fusion protein platform to develop and manufacture new classes of biologics, including vaccines, ultra-long-acting insulins, and autoimmune disease therapies. It was founded in 2011 and headquartered in Beverly, Massachusetts. | Series H / Apr 30, 2025 | |
Zenflow
|
Zenflow was founded in 2014 by a team of Stanford University Biodesign Fellows working in collaboration with top global urologists. After witnessing patients' frustration with existing treatment options, the founders made it their mission to find a better solution to this large unmet clinical need. | $24M / Series C / Nov 18, 2024 | |
AMPRION
|
Amprion is a biotech company that focuses on the diagnosis of brain diseases like Parkinson’s, Alzheimer’s, and Lewy Body Dementia. The company was founded in 2007 and is headquartered in San Francisco, California, United States. | $5.8M / Sep 25, 2024 | |
| See all 108 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Featured in Investor Lists
Recommended lists
FAQ
What does Propel(X) invest in?
Propel(X) invests primarily in Health Care, Biotechnology and Software startups, most often at Seed and Series A stage. Most of the 108 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Propel(X)'s check size?
Propel(X) typically joins rounds of $702k–$4M at Seed, $1.8M–$20M at Series A and $2M–$41M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Propel(X) participates in.
How do I contact Propel(X)?
Public channels for Propel(X) include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Propel(X)?
The team at Propel(X) includes Andy Reed (Director), Anand V. (Evaluation Contributor - Science and Technology Startups) and Jason Holt (Venture Partner), among 9 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
